Featured Research

from universities, journals, and other organizations

Hamburger Disease Drug Put To The Test

Date:
July 31, 2003
Source:
McGill University
Summary:
A research study, testing a new treatment for hamburger disease, was launched today at The Montreal Children's Hospital of the McGill University Health Centre (MUHC). The study conducted by investigators from the Research Institute of the MUHC and from The Children's, will test the ability of this treatment to stop disease progression in children.

A research study, testing a new treatment for hamburger disease, was launched today at The Montreal Children's Hospital of the McGill University Health Centre (MUHC). The study conducted by investigators from the Research Institute of the MUHC and from The Children's, will test the ability of this treatment to stop disease progression in children.

"Hamburger disease", or hemolytic uremic syndrome (HUS), affects more than 3 000 North Americans annually and is one the leading causes of acute and chronic kidney failure in children. It usually occurs following a gastrointestinal infection caused by a strain of bacteria called E.coli O157:H7. This bacterium has been associated with eating undercooked ground beef and drinking contaminated water, unpasteurized milk, or apple juice. The organism was involved in the Walkerton epidemic several years ago.

"Currently, there is no effective treatment for HUS," says MUHC pediatrician and lead investigator Dr. Paul Goodyer. "Approximately, ten percent of E.coli-infected patients, many of whom are children, develop HUS. About half of the HUS patients require dialysis and even with comprehensive medical care four to five percent of these patients will die. Thirty percent to fifty percent of the survivors will develop long-term complications such as chronic kidney disease and nervous system disorders. Clearly, we need treatment for this disease."

The MUHC is one of six Canadian centres testing this new treatment. The treatment involves administrating an antibody to the toxin produced by E.coli O157:H7. "We expect that this antibody will inactivate the toxin in the bloodstream at an early enough stage to prevent damage to kidneys and brain," says MUHC emergency room physician and co-investigator Dr. Dominic Chalut.

Children seen at the Montreal Children's Hospital Emergency Department who have bloody diarrhea for less than 72 hours and whose stools test positive for E.coli O157:H7 are eligible for the study. Following administration of the treatment, blood and urine samples will be taken and disease progression will be assessed. The children will be followed for a total of four months.


Story Source:

The above story is based on materials provided by McGill University. Note: Materials may be edited for content and length.


Cite This Page:

McGill University. "Hamburger Disease Drug Put To The Test." ScienceDaily. ScienceDaily, 31 July 2003. <www.sciencedaily.com/releases/2003/07/030731082409.htm>.
McGill University. (2003, July 31). Hamburger Disease Drug Put To The Test. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2003/07/030731082409.htm
McGill University. "Hamburger Disease Drug Put To The Test." ScienceDaily. www.sciencedaily.com/releases/2003/07/030731082409.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Pregnancy Spacing Could Have Big Impact On Autism Risks

Pregnancy Spacing Could Have Big Impact On Autism Risks

Newsy (Oct. 1, 2014) A new study says children born less than one year and more than five years after a sibling can have an increased risk for autism. Video provided by Newsy
Powered by NewsLook.com
Robotic Hair Restoration

Robotic Hair Restoration

Ivanhoe (Oct. 1, 2014) A new robotic procedure is changing the way we transplant hair. The ARTAS robot leaves no linear scarring and provides more natural results. Video provided by Ivanhoe
Powered by NewsLook.com
Insertable Cardiac Monitor

Insertable Cardiac Monitor

Ivanhoe (Oct. 1, 2014) A heart monitor the size of a paperclip that can save your life. The “Reveal Linq” allows a doctor to monitor patients with A-Fib on a continuous basis for up to 3 years! Video provided by Ivanhoe
Powered by NewsLook.com
Attacking Superbugs

Attacking Superbugs

Ivanhoe (Oct. 1, 2014) Two weapons hospitals can use to attack superbugs. Scientists in Ireland created a new gel resistant to superbugs, and a robot that can disinfect a room in minutes. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins